CLDXHealthcare · BiotechnologyThe 15 Wall Street analysts covering Celldex Therapeutics, Inc. hold a median 12-month price target of $64 — +113.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Celldex Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (68): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (14): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CLDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +113.8% from it.
Of the 20 most recent actions, 8 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $64 |
| 23 Sept 2026 | Leerink Partners | Maintains | Outperform | $70 → $88 |
| 23 Sept 2026 | Leerink Partners | Maintains | Outperform | — |
| 23 Sept 2026 | Morgan Stanley | Maintains | Overweight | $50 → $57 |
| 23 Sept 2026 | Morgan Stanley | Maintains | Overweight | — |
| 22 Sept 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 22 Sept 2026 | Cantor Fitzgerald | Maintains | Overweight | $61 → $72 |
| 22 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $42 → $64 |
| 10 Sept 2026 | Morgan Stanley | Maintains | Overweight | $46 → $50 |
| 10 Sept 2026 | Morgan Stanley | Maintains | Overweight | — |
| 7 Aug 2026 | Barclays | Maintains | Overweight | — |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $48 → $53 |
| 7 Aug 2026 | Morgan Stanley | Maintains | Overweight | $40 → $46 |
| 7 Aug 2026 | Morgan Stanley | Maintains | Overweight | — |
| 29 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 29 July 2026 | Wells Fargo | Maintains | Overweight | $48 → $72 |
| 22 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 22 July 2026 | Canaccord Genuity | Maintains | Buy | $62 → $60 |
| 22 July 2026 | Cantor Fitzgerald | Maintains | Overweight | $67 → $61 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CLDX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Celldex Therapeutics, Inc. returned +25.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 1% of US stocks
Cheaper than 28% of US stocks
Cheaper than 81% of US stocks
Higher than 2% of US stocks
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 23% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Celldex Therapeutics, Inc. has a market value of $2.3B and an enterprise value of $1.6B.
Revenue in the twelve months to 30 June 2026: $158K. The latest quarter shrank 97.0% year on year.
Net income over the same four quarters: −$300.5M, a −190220.9% net margin.
Diluted earnings per share, trailing twelve months: $−4.35.
Free cash flow in the twelve months to 30 June 2026: −$242.1M.
Trailing P/E: −7.6×; forward P/E: −7.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Celldex Therapeutics, Inc. employs 198 people — $798.0 of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Celldex Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Celldex announced that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026, at 9:00 a.m. ET.
Why it matters — The announcement provides CLDX watchers with details about an upcoming opportunity to hear from company management.
Purcell & Lefkowitz LLP said it is investigating Celldex Therapeutics on behalf of shareholders to determine whether directors breached fiduciary duties in connection with recent corporate actions.
Why it matters — The investigation concerns the conduct of Celldex’s directors and may be relevant to shareholders monitoring the company’s recent corporate actions.
Celldex Therapeutics held a discussion regarding positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria, as reported by Seeking Alpha. The item is a transcript of the company discussing these results.
Why it matters — CLDX watchers would care because the positive Phase 3 results for barzolvolimab represent a potentially significant milestone for one of the company's key development programs.
Celldex Therapeutics shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating barzolvolimab for chronic spontaneous urticaria (CSU) in patients with inadequate symptom control using H1-antihistamines, including those who are advanced therapy experienced or refractory.
Why it matters — A CLDX watcher would care because these Phase 3 topline results for barzolvolimab represent a key clinical milestone for the company's lead candidate in treating chronic spontaneous urticaria.
Celldx Therapeutics reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria who remained symptomatic despite H1 antihistamine treatment. Both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.
Why it matters — These successful Phase III results for barzolvolimab represent a significant clinical advancement for a key product in Celldx's pipeline.
The 15 Wall Street analysts covering Celldex Therapeutics, Inc. have a median 12-month price target of $64, with estimates ranging from $28 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Celldex Therapeutics, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Celldex Therapeutics, Inc. 24 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Celldex Therapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (68 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +113.8% from the last close, and Ticker Nerd's factor model ranks Celldex Therapeutics, Inc. 24 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Celldex Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $100 over the next 12 months.
Celldex Therapeutics, Inc. returned +25.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
The most recent item we track (GlobeNewsWire, 4 Nov 2026): "Celldex to Present at Upcoming Investor Conferences". Celldex announced that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026, at 9:00 a.m. ET.
Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases. The company’s current programs center on monoclonal and bispecific antibodies designed to modulate mast cell biology and other immune pathways associated with chronic conditions that have limited treatment options. Its lead clinical assets include barzolvolimab, a KIT-targeting antibody being studied across several mast cell–driven disorders, and CDX-622, a bispecific candidate aimed at key inflammatory mechanisms. Celldex Therapeutics Inc. operates in the biotechnology sector and concentrates on advancing immunology-focused therapies through clinical development for patients with significant unmet medical needs. Headquartered in Hampton, New Jersey, the company is known for its specialized pipeline rather than a broad commercial product portfolio.
CEO Mr. Anthony S. Marucci M.B.A. · 198 employees · United States · https://www.celldex.com
